Revelation Biosciences Earnings Call Transcripts

Fiscal Year 2026

Transcript

Gemini, a novel anti-inflammatory therapy, is advancing to a pivotal adaptive phase II/III trial for acute kidney injury, with FDA support for a composite endpoint and efficient study design. Strong clinical and preclinical data support broad potential, and cash runway extends into Q1 2027.

Read full transcript →